Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to a specific share transaction notification and does not contain financial statements or performance metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only reported change is an increase in the personal shareholding of Ms. C. Thomas.
Management Commentary and Risks
The filing details a transaction on January 9, 2014, where Ms. C. Thomas acquired 33,853 Ordinary Shares. This purchase was executed at a price of 1,651.50 pence per share and resulted from the re-investment of dividends paid to shareholders on that date. The company was informed of this transaction on February 10, 2014, in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a). No other risks, contingencies, or outlook guidance are provided in this specific report.
Key Facts for Investor Verification
- Transaction Date: January 9, 2014.
- Individual: Ms. C. Thomas (Person Discharging Managerial Responsibility).
- Shares Acquired: 33,853 Ordinary Shares.
- Price per Share: 1,651.50 pence.
- Transaction Type: Dividend re-investment.
- Notification Date: February 10, 2014.